{"analyses":[{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0192","paramType":"Hazard Ratio (HR)","paramValue":"0.44","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated, estimates cannot be calculated due to too few events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA - Not calculated, estimates cannot be calculated due to too few events.","groupId":"OG001","lowerLimit":"5.39","upperLimit":"NA","value":"9.92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \\[Item 3\\] and Analgesic Quantification Algorithm \\[AQA\\] score.","dispersionType":"95% Confidence Interval","groups":[{"description":"2x150mg film-coated tablets","id":"OG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"OG001","title":"Cohort A Investigators Choice of NHA"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Every 4 weeks from randomisation (for 7 consecutive days) throughout the study (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","title":"Time to Pain Progression - Cohort A Only","type":"SECONDARY","unitOfMeasure":"Months"}